Status:
ACTIVE_NOT_RECRUITING
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
Lead Sponsor:
Eisai Co., Ltd.
Conditions:
Lymphoma, Follicular
Eligibility:
All Genders
Brief Summary
The primary purpose of the study is to investigate the safety of tazemetostat in participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation under daily clinical practice.
Eligibility Criteria
Inclusion
- Participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation
- Participants treated with tazemetostat
Exclusion
- 1\. Participants with a history of hypersensitivity to any ingredient of Tazverik
Key Trial Info
Start Date :
August 16 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2028
Estimated Enrollment :
145 Patients enrolled
Trial Details
Trial ID
NCT05228158
Start Date
August 16 2021
End Date
March 31 2028
Last Update
January 2 2026
Active Locations (135)
Enter a location and click search to find clinical trials sorted by distance.
1
Eisai Trial Site 131
Komaki-shi, Aichi-ken, Japan
2
Eisai Trial Site 199
Konan-shi, Aichi-ken, Japan
3
Eisai Trial Site 21
Nagakute-shi, Aichi-ken, Japan
4
Eisai Trial Site 106
Nagoya, Aichi-ken, Japan